Figure 1A–D. The effects of EMMPRIN knockdown on the aggressive phenotypes of ovarian carcinoma cells. The mRNA and protein expressions of EMMPRIN were screened in ovarian carcinoma cells (OVCAR3, SKOV3, SKOV3/DDP, HO8910, HO8910/pm, HO8910, ES-2, and CAOV3) by real-time PCR (A) and western blot (B), respectively. EMMPRIN proteins were classified into Core protein (27kDa), less-glycosylated (~32–44 kDa, LG) and highly glycosylated form (~45–65 kDa, HG). After transfection of EMMPRIN siRNA, its expression was reduced in OVCAR3, SKOV3/DDP, and HO8910/pm cells by real-time RT-PCR (C) and western blot (D) compared with control (CTR), and mock cells. The transfectants showed lower growth by CCK-8 (E), no significantly lower proliferation with DDP treatment by CCK-8 (F), G₁ arrest by PI staining (G), higher apoptosis by Annexin V staining (H), lower migration by wound healing (I), and weaker invasion by transwell (J) than the control and mock cells. After the treatment of EMMPRIN siRNA, there was reduced expression of Wnt5a, Akt, p70s6k, Bcl-xL, survivin, VEGF, and MMP-9 at both mRNA and protein levels in OVCAR3, SKOV3/DDP, and HO8910/pm cells by real-time PCR (K) and western blot (L). * P < 0.05. Results are representative of 3 different experiments, and data are expressed as mean ± standard deviation with the control as “1”.